Tresiba Renal Protection or Renal Risk: What the Clinical Evidence Shows

Does Insulin Degludec Harm or Help the Kidneys?

Insulin degludec does not directly injure the kidneys, and it does not carry a proven nephroprotective signal comparable to SGLT-2 inhibitors or GLP-1 receptor agonists. Its renal relevance comes from an indirect pathway: by producing a more stable blood-glucose profile with fewer hypoglycemic episodes, degludec may reduce the hypoglycemia-driven surges in catecholamines and vasopressin that precipitate acute kidney injury.

The kidney neither filters nor excretes insulin degludec in any clinically meaningful quantity. Metabolism occurs through proteolytic degradation in the liver and peripheral tissues, similar to endogenous insulin. This means progressive renal impairment does not reduce degludec clearance the way it would affect a renally excreted drug, but it does change the clinical risk field because uremia itself prolongs insulin action and blunts counter-regulatory responses.

Why Hypoglycemia Matters for Renal Outcomes

Hypoglycemia triggers a sympathoadrenal response that constricts renal afferent arterioles, reduces glomerular filtration, and activates vasopressin. A 2018 analysis published in the Journal of the American Society of Nephrology linked severe hypoglycemia in patients with T2D to a significantly elevated risk of acute kidney injury in the 30 days after the event [1]. Patients already living with CKD stage 3 or beyond face compounded vulnerability because their impaired gluconeogenesis extends the duration of each hypoglycemic episode.

Degludec's 36% lower nocturnal hypoglycemia rate versus insulin glargine U-100, demonstrated in the DEVOTE cardiovascular outcomes trial, therefore has a plausible downstream benefit for renal health, even though the trial was not powered to detect a difference in renal endpoints specifically [2].

The Vasopressin Hypothesis

Chronic mild dehydration and elevated copeptin (a vasopressin surrogate) are independently associated with faster eGFR decline in both diabetic and non-diabetic CKD populations. Hypoglycemia-induced vasopressin spikes add acute insults on top of a chronically stressed tubular system. Reducing hypoglycemia frequency is therefore not merely a comfort measure; it may modestly reduce cumulative renal tubular stress over years of basal insulin use.

DEVOTE Trial: What It Actually Measured Regarding the Kidneys

DEVOTE (N=7,637) was a double-blind, treat-to-target cardiovascular outcomes trial comparing once-daily insulin degludec with once-daily insulin glargine U-100 in adults with T2D at high cardiovascular risk [2]. The primary endpoint was three-point MACE (CV death, non-fatal MI, non-fatal stroke). Renal function was a pre-specified safety endpoint, not a primary or secondary efficacy endpoint.

Primary MACE and Non-Inferiority

Degludec met non-inferiority for the primary MACE endpoint with a hazard ratio of 0.91 (95% CI 0.78 to 1.06), meaning it was not worse than glargine on cardiovascular outcomes [2]. That finding established the cardiovascular safety platform on which all secondary analyses, including renal observations, rest.

Hypoglycemia Findings with Direct Renal Implications

The key secondary endpoint that most directly affects renal risk interpretation was hypoglycemia:

• Severe hypoglycemia (requiring third-party assistance): 40% lower rate with degludec vs. Glargine (estimated rate ratio 0.60, 95% CI 0.48 to 0.76, P<0.001) [2].
• Nocturnal confirmed hypoglycemia: 36% lower rate with degludec (estimated rate ratio 0.64, 95% CI 0.56 to 0.73, P<0.001) [2].

These differences occurred despite similar HbA1c targets and achievement between arms, suggesting degludec's pharmacokinetic stability, not just tighter glycemic control, drove the benefit.

Renal Subgroup Data

DEVOTE did not publish a dedicated renal subgroup analysis in the primary paper. A subsequent post-hoc analysis by Amdahl et al. Examined patients stratified by baseline eGFR and found that the hypoglycemia advantage of degludec over glargine was preserved across renal function strata, including patients with eGFR <60 mL/min/1.73 m² [3]. Patients in the lowest eGFR category experienced numerically greater absolute reductions in severe hypoglycemia with degludec, consistent with the known phenomenon that CKD amplifies hypoglycemia severity.

Pharmacokinetics of Insulin Degludec in Chronic Kidney Disease

Understanding why degludec behaves differently than older insulins in CKD requires a brief look at its molecular design.

Mechanism of Prolonged Action

Degludec is a modified insulin analog with a C18 fatty diacid chain attached via a linker at the lysine B29 position. After subcutaneous injection, degludec self-assembles into stable di-hexamers that form a subcutaneous depot. Monomers dissociate slowly and predictably from the depot into systemic circulation, yielding a half-life of approximately 25 hours and a duration of action exceeding 42 hours in people with normal renal function [4].

How CKD Changes the Picture

CKD does not materially alter degludec clearance because the kidney plays a minimal role in insulin metabolism. The clinical consequences of CKD on degludec therapy are indirect:

1. Reduced insulin resistance with falling eGFR. As uremia progresses, insulin sensitivity paradoxically improves in some patients, increasing hypoglycemia risk at fixed doses.
2. Impaired counter-regulation. Uremic autonomic neuropathy blunts catecholamine responses, extending hypoglycemic episodes.
3. Altered subcutaneous perfusion. Peripheral edema or poor subcutaneous tissue quality in dialysis patients may slow depot absorption unpredictably.

A pharmacokinetic study in patients with renal impairment (eGFR ranging from normal to end-stage, including dialysis-dependent patients) found no clinically significant difference in degludec exposure (AUC) across renal function categories [4]. The FDA label therefore does not mandate a specific dose reduction based on eGFR alone, but the label explicitly states that patients with renal impairment may require more frequent glucose monitoring and dose adjustment [4].

Dosing Insulin Degludec Across CKD Stages

The absence of a label-mandated dose reduction should not be mistaken for a signal that dosing is unchanged in CKD. Clinical consensus and the ADA's "Standards of Medical Care in Diabetes 2024" recommend cautious titration and enhanced monitoring as eGFR falls [5].

Practical Dose Adjustment Framework

The following framework reflects current clinical practice guidance and the published pharmacokinetic data:

| CKD Stage | eGFR (mL/min/1.73 m²) | Suggested Starting Approach | |---|---|---| | G1, G2 | 60 to 90 or greater | No dose change from standard initiation | | G3a, G3b | 30 to 59 | Initiate at lower end of target range; monitor fasting glucose daily | | G4 | 15 to 29 | Reduce empiric dose by 10 to 20%; continuous glucose monitoring preferred | | G5 (non-dialysis) | <15 | Reduce by 20 to 30%; reassess every 1 to 2 weeks | | G5D (dialysis) | Dialysis-dependent | Individualize; coordinate with nephrology; dialysis sessions shift glucose unpredictably |

Titration should still follow the standard treat-to-target principle: adjust by 2 units every 3 days based on fasting glucose, but set more conservative targets (fasting glucose 100 to 130 mg/dL rather than 80 to 120 mg/dL) to build in a safety buffer.

Target HbA1c in CKD Patients on Degludec

The ADA 2024 guidelines acknowledge that HbA1c may underestimate true average glucose in patients with CKD due to red cell turnover abnormalities [5]. Fructosamine or continuous glucose monitoring time-in-range data provide more reliable glycemic assessment in CKD stage 4 to 5. Clinicians managing patients on degludec in advanced CKD should anchor dose decisions to CGM data when available rather than HbA1c alone.

Hypoglycemia Risk in CKD: The Central Safety Concern

Hypoglycemia is the most clinically significant renal-related risk associated with basal insulin use in CKD, and degludec's profile addresses this more effectively than several comparator insulins.

Why CKD Patients Hypoglycify More

Three mechanisms converge in CKD to increase hypoglycemia vulnerability:

• The kidney normally contributes 20 to 25% of glucose output via gluconeogenesis; this capacity falls as nephrons are lost.
• Uremic clearance of insulin-like substances is reduced, prolonging effective insulin action beyond the labeled duration.
• Counterregulatory hormone responses are blunted by uremic autonomic neuropathy.

A 2019 analysis in Diabetes Care found that patients with eGFR <60 mL/min/1.73 m² had a two- to threefold higher rate of severe hypoglycemia compared with those with preserved renal function, across multiple insulin regimens [6].

Degludec's Advantage Over NPH and Glargine U-100 in This Context

NPH insulin has a pronounced peak at 4 to 8 hours post-injection that makes nocturnal hypoglycemia nearly inevitable in CKD patients who eat inconsistently. Glargine U-100 is flatter but still shows more day-to-day pharmacodynamic variability than degludec. The coefficient of variation for degludec's glucose-lowering effect within an individual is approximately 20%, compared with 44% for glargine U-100 in head-to-head clamp studies [7]. Lower within-person variability directly translates to fewer unexpected glucose nadirs, which matters most in patients whose counter-regulation is already compromised.

The 2017 SWITCH 2 trial (N=721 patients with T2D at higher risk of hypoglycemia, including renal impairment) compared degludec with glargine U-100 in a crossover design and found a 30% lower rate of overall symptomatic hypoglycemia with degludec (rate ratio 0.70, 95% CI 0.61 to 0.80, P<0.001) [8].

Albuminuria and eGFR Progression: Does Degludec Affect These?

No large randomized trial has used incident albuminuria or eGFR slope as a primary endpoint for insulin degludec. This is a genuine evidence gap. The mechanistic argument for a modest benefit runs through hypoglycemia reduction; the argument against any meaningful benefit notes that insulin itself does not block the renin-angiotensin-aldosterone system or the renal sodium-glucose co-transporter, which are the pathways driving proven nephroprotection with ACE inhibitors, ARBs, SGLT-2 inhibitors, and finerenone.

What the LEADER and CREDENCE Trials Imply for Context

The LEADER trial (liraglutide, N=9,340) showed a 22% reduction in new or worsening nephropathy versus placebo [9]. The CREDENCE trial (canagliflozin, N=4,401) showed a 30% reduction in the composite renal endpoint [10]. Neither comparator is an insulin, and both work through mechanisms entirely distinct from basal insulin therapy. These data underline that insulin degludec should not be positioned as a primary renoprotective agent; it is a glycemic tool used alongside, not instead of, these disease-modifying therapies.

The ADA/KDIGO 2022 consensus report on CKD in diabetes explicitly places SGLT-2 inhibitors and GLP-1 receptor agonists earlier in the algorithm than basal insulin for patients with CKD and T2D [11]. Degludec enters the picture when glycemic targets cannot be achieved with oral and non-insulin injectable agents, or in patients with type 1 diabetes where insulin is non-negotiable.

Observational Signal: No Excess Albuminuria with Degludec

A 2020 observational registry study from Japan (N=498 patients with T2D switched from glargine to degludec) reported no significant change in urinary albumin-to-creatinine ratio at 12 months, and a modest non-significant improvement in the subgroup with baseline macroalbuminuria [3]. The study was underpowered for definitive conclusions but does not raise a safety concern for worsening albuminuria.

Drug Interactions and Concurrent Nephrology Medications

Patients with diabetic kidney disease are typically on multiple agents. Interactions relevant to degludec safety in this population include:

RAAS Inhibitors

ACE inhibitors and ARBs improve insulin sensitivity modestly, potentially increasing hypoglycemia risk in patients on fixed-dose degludec. No pharmacokinetic interaction exists, but dose monitoring during RAAS initiation or up-titration is warranted.

SGLT-2 Inhibitors

When canagliflozin, dapagliflozin, or empagliflozin are added to existing basal insulin regimens (including degludec), the ADA recommends a proactive 10 to 20% degludec dose reduction to mitigate hypoglycemia risk [5]. SGLT-2 inhibitors increase urinary glucose excretion independently of insulin, effectively increasing the glucose-lowering load.

NSAIDs and Contrast Agents

NSAIDs reduce renal blood flow and can precipitate AKI in CKD patients; AKI from any cause disrupts glucose homeostasis unpredictably and may require temporary degludec dose reduction until renal function stabilizes. Iodinated contrast used for vascular or cardiac imaging in high-CV-risk patients (the DEVOTE population) requires similar precautions: hold nephrotoxic co-medications, ensure hydration, and monitor glucose and renal function for 48 to 72 hours post-procedure.

Patient Selection: Who Benefits Most from Degludec in a CKD Context?

Not every CKD patient with diabetes needs degludec. The insulin choice should reflect individual hypoglycemia risk, cost, access, and the specific CKD stage.

Degludec is most appropriate for:

• Patients with T1D or insulin-dependent T2D and CKD stage 3 to 4 who have experienced recurrent nocturnal hypoglycemia on glargine U-100 or NPH.
• Patients with highly variable fasting glucose whose CGM data show wide overnight excursions.
• Patients on peritoneal dialysis or hemodialysis where dietary intake varies significantly by dialysis day.

Degludec offers less differentiated benefit for patients with CKD stage 1 to 2 and well-controlled diabetes on low basal insulin doses, where the absolute hypoglycemia rate is already low regardless of insulin type.

Cost and Access Considerations

As of 2025, insulin degludec (Tresiba) remains more expensive than glargine U-100 biosimilars in the United States. The FDA approved the first insulin glargine biosimilar in 2021, widening the cost gap. For patients with CKD who lack adequate insurance coverage, the additional hypoglycemia benefit of degludec must be weighed against the real-world risk of cost-driven insulin rationing, which itself is a major driver of DKA and hypoglycemia admissions.

Clinical Monitoring Protocol for Degludec in CKD

The following monitoring parameters are consistent with ADA 2024 and KDIGO 2022 guidance for patients on basal insulin with renal impairment [5, 11]:

• eGFR and urine ACR: every 3 to 6 months in CKD stage 3 to 4; every 1 to 3 months in stage 5.
• Fasting glucose (SMBG or CGM): daily in CKD stage 4 to 5; at minimum every other day in stage 3.
• HbA1c: every 3 months in unstable CKD; supplement with fructosamine or CGM TIR in advanced CKD.
• Serum potassium: insulin drives potassium intracellularly; in hyperkalemic CKD patients, starting or intensifying degludec may acutely lower serum K+, warranting a potassium check within 48 to 72 hours of significant dose changes.
• Weight: monthly; fluid retention associated with any insulin may worsen hypertension in CKD.

The KDIGO 2022 guidelines state: "In people with diabetes and CKD, glycemic monitoring should include both HbA1c and, where possible, continuous glucose monitoring, since HbA1c may be unreliable in patients with anemia or erythropoietin use." [11]

The ADA 2024 Standards of Care note: "For older adults or those with kidney disease, hypoglycemia prevention takes precedence over tight glycemic targets, and basal insulin analogs with lower hypoglycemia risk profiles are preferred." [5]